Immunomodulatory therapy for the treatment of ocular inflammatory disease: Evidence-based medicine recommendations for use

International Ophthalmology Clinics

Volumn 46, Issue 2, 2006, Pages 141-164

  Christina Kim, Eva ^a   Stephen Foster, C ^b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b Massachusetts Eye Research and Surgery Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALLOPURINOL; ALPHA INTERFERON; ANTIMETABOLITE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; DACLIZUMAB; ETANERCEPT; FOLIC ACID; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR; LEFLUNOMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TETRAHYDROFOLIC ACID; THIOPURINE METHYLTRANSFERASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALOPECIA; AMENORRHEA; ANKYLOSING SPONDYLITIS; ANOREXIA; AUTOIMMUNE DISEASE; BEHCET DISEASE; BLADDER DISEASE; BLINDNESS; BONE MARROW APLASIA; BONE MARROW SUPPRESSION; CANCER; CARDIAC GRAFT REJECTION; CELLULITIS; CHORIORETINOPATHY; CHOROIDITIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; CROHN DISEASE; CROSS LINKING; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DERMATOMYOSITIS; DIARRHEA; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DYSPNEA; EVIDENCE BASED MEDICINE; EYE INFLAMMATION; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAFT REJECTION; GUILLAIN BARRE SYNDROME; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HERPES SIMPLEX; HUMAN; HYPERKALEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTRICHOSIS; HYPOMAGNESEMIA; IMMUNE DEFICIENCY; IMMUNOMODULATION; INCIDENCE; INFECTION; INFERTILITY; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; INTERSTITIAL NEPHRITIS; INTERSTITIAL PNEUMONIA; INTRAOCULAR HYPERTENSION; KIDNEY GRAFT REJECTION; KIRISAWA UVEITIS; LEUKOPENIA; LIVER CIRRHOSIS; LIVER TOXICITY; LYMPHOMA; MALE STERILITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MUCOUS MEMBRANE PEMPHIGOID; MYALGIA; MYOSITIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NUCLEOTIDE METABOLISM; OPPORTUNISTIC INFECTION; PARESTHESIA; PLASMA CELL GRANULOMA; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REITER SYNDROME; RETINA HEMORRHAGE; RETINA VASCULITIS; RHEUMATOID ARTHRITIS; SCLERITIS; SKIN CANCER; STOMACH PAIN; STOMATITIS; SYMPATHETIC OPHTHALMIA; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TERATOGENICITY; TREMOR; TUBERCULOSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; UVEITIS; VIRUS INFECTION; VISUAL ACUITY; WEGENER GRANULOMATOSIS;

EID: 33746114478     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200604620-00013     Document Type: Conference Paper

References (130)

1. Mercanti A, Parolini B, Bonora A, et al. Epidemiology of endogenous uveitis in north-eastern Italy. Analysis of 655 new cases. Acta Ophthalmol Scand. 2001;79:64-68.
2. Smit RL, Baarsma GS. Epidemiology of uveitis. Curr Opin Ophthalmol. 1995;6:57-61.
3. Baarsma GS. The epidemiology and genetics of endogenous uveitis: a review. Curr Eye Res. 1992;11:1-9.
4. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14:303-308.
5. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80:844-848.
6. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332-336.
7. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.
8. Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis. 1994;18:421.
9. Zimmerman TJ. Textbook of Ocular Pharmacology. Philadelphia: Lippincott-Raven; 1997:100-101.
10. Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 1992;99:1419-1423.
11. Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994;37:316-328.
12. Kremer JM. Methotrexate and emerging therapies. Clin Exp Rheumatol. 1999;17:543-546.
13. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum. 2004;50:1370-1382.
14. Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr. 1998;133:266-268.
15. Holz FG, Krastel H, Breitbart A, et al. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol. 1992;1:142-144.
16. Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology. 1999;106:111-118.
17. Bom S, Zamiri P, Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm. 2000;9:35-40.
18. Samson CM, Waheed N, Baltatzis S, et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108:1134-1139.
19. Kaplan-Messas A, Barkana Y, Avni I, et al. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm. 2003;11:131-139.
20. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2005;32:362-365.
21. Elion GB. Pharmacologic and physical agents. Immunosuppressive agents. Transplant Proc. 1977;9:975-979.
22. Van OE, Zins BJ, Sandborn WJ, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral, and rectal foam administration. Gut. 1996;39:63-68.
23. Chan GL, Erdmann GR, Gruber SA, et al. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol. 1990;30:358-363.
24. Singh G, Fries JF, Spitz P, et al. Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum. 1989;32:837-843.
25. Tsokos GC. Immunomodulatory treatment in patients with rheumatic diseases: mechanisms of action. Semin Arthritis Rheum. 1987;17:24-38.
26. Calin A. A placebo controlled, crossover study of azathioprine in Reiter's syndrome. Ann Rheum Dis. 1986;45:653-655.
27. Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology. 1975;69:96-99.
28. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med. 1984;311:1528-1533.
29. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990;322:281-285.
30. Yazici H, Fresko I, Hamuryudan V, et al. Behcet's syndrome. The Cerrahpasa experience. Members of the Behcet's Syndrome Research Centre. Adv Exp Med Biol. 1999;455:135-140.
31. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40:769-774.
32. Newell FW, Krill AE. Treatment of uveitis with azathioprine (Imuran). Trans Ophthalmol Soc UK. 1967;87:499-511.
33. Mathews JD, Crawford BA, Bignell JL, et al. Azathioprine in active chronic iridocyclitis. A double-blind controlled trial. Br J Ophthalmol. 1969;53:327-330.
34. Andrasch RH, Pirofsky B, Burns RP. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol. 1978;96:247-251.
35. Hooper PL, Kaplan HJ. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology. 1991;98:944-951.
36. Akpek EK, Baltatzis S, Yang J, et al. Long-term immunosuppressive treatment of serpiginous choroiditis. Ocul Immunol Inflamm. 2001;9:153-167.
37. Michel SS, Ekong A, Baltatzis S, et al. Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology. 2002;109:378-383.
38. Gion N, Stavrou P, Foster CS. Immunomodulatory therapy for chronic tubulointerstitial nephritis-associated uveitis. Am J Ophthalmol. 2000;129:764-768.
39. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet. 1995;345:1321-1325.
40. Blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1996;61:1029-1037.
41. Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet. 1998;352:35-36.
42. Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology. 1999;106:370-374.
43. Baltatzis S, Tufail F, Yu EN, et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology. 2003;110:1061-1065.
44. Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Exp Ophthalmol. 2003;31:487-491.
45. Sen HN, Suhler EB, Al-Khatib SQ, et al. Mycophenolate mofetil for the treatment of scleritis. Ophthalmology. 2003;110:1750-1755.
46. Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 2: the newer drugs and drug strategies. Am J Ther. 2001;8:163-179.
47. Robertson SM, Lang LS. Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats. Agents Actions. 1994;42:167-172.
48. Hogan PG, Chen L, Nardone J, et al. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 2003;17:2205-2232.
49. BenEzra D, Maftzir G, de Courten C, et al. Ocular penetration of cyclosporin A. III: The human eye. Br J Ophthalmol. 1990;74:350-352.
50. Palestine AG, Austin HA III, Balow JE, et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med. 1986;314:1293-1298.
51. Keown PA, Primmett DR. Cyclosporine: the principal immunosuppressant for renal transplantation. Transplant Proc. 1998;30:1712-1715.
52. McCune WJ, Friedman AW. Immunosuppressive drug therapy for rheumatic disease. Curr Opin Rheumatol. 1993;5:282-292.
53. Nussenblatt RB, Palestine AG, Rook AH, et al. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet. 1983;2:235-238.
54. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983;96:275-282.
55. Graham EM, Sanders MD, James DG, et al. Cyclosporin A in the treatment of posterior uveitis. Trans Ophthalmol Soc UK. 1985;104:146-151.
56. Towler HM, Cliffe AM, Whiting PH, et al. Low close cyclosporin A therapy in chronic posterior uveitis. Eye. 1989;3:282-287.
57. Towler HM, Whiting PH, Forrester JV. Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation. Eye. 1990;4: 514-520.
58. Wakefield D, McCluskey P. Cyclosporine: a therapy in inflammatory eye disease. J Ocul Pharmacol. 1991;7:221-226.
59. Secchi AG, De Rosa C, Pivetti-Pezzi P, et al. Open noncontrolled multicenter long-term trial with ciclosporin in endogenous non-infectious uveitis. Ophthalmologica. 1991;202:217-224.
60. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology. 1996;103:365-73.
61. de Vries J, Baarsma GS, Zaal MJ, et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol. 1990;74:344-349.
62. Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol. 1991;112:138-146.
63. Nussenblatt RB, de Smet MD, Rubin B, et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. Am J Ophthalmol. 1993;115:583-591.
64. Binder AI, Graham EM, Sanders MD, et al. Cyclosporin A in the treatment of severe Behcet's uveitis. Br J Rheumatol. 1987;26:285-291.
65. Muftuoglu AU, Pazarli H, Yurdakul S, et al. Short term cyclosporin A treatment of Behcet's disease. Br J Ophthalmol. 1987;71:387-390.
66. Diaz-Llopis M, Cervera M, Menezo JL. Cyclosporin A treatment of Behcet's disease: a long-term study. Curr Eye Res. 1990;9:17-23.
67. Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol. 1992;76:241-243.
68. Whitcup SM, Salvo EC Jr, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol. 1994;118:39-45.
69. Sajjadi H, Soheilian M, Ahmadieh H, et al. Low dose cyclosporin-A therapy in Behcet's disease. J Ocul Pharmacol. 1994;10:553-560.
70. Ozdal PC, Ortac S, Taskintuna I, et al. Long-term therapy with low dose cyclosporin A in ocular Behcet's disease. Doc Ophthalmol. 2002;105:301-312.
71. BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc. 1988;20:136-143.
72. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet. 1989;1:1093-1096.
73. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology. 1994;101:822-831.
74. Secchi AG, Tognon MS, Maselli C. Cyclosporine-A in the treatment of serpiginous choroiditis. Int Ophthalmol. 1990;14:395-399.
75. Chan CC, Roberge RG, Whitcup SM, et al. 32 cases of sympathetic ophthalmia. A retrospective study at the National Eye Institute, Bethesda, MD, from 1982 to 1992. Arch Ophthalmol. 1995;113:597-600.
76. Wakefield D, McCluskey P. Cyclosporin therapy for severe scleritis. Br J Ophthalmol. 1989;73:743-746.
77. McCarthy JM, Dubord PJ, Chalmers A, et al. Cyclosporine A for the treatment of necrotizing scleritis and corneal melting in patients with rheumatoid arthritis. J Rheumatol. 1992;19:1358-1361.
78. Neumann R, Tauber J, Foster CS. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology. 1991;98:858-862.
79. Foster CS, Neumann R, Tauber J. Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid. Doc Ophthalmol. 1992;82:223-229.
80. Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med. 1971;285:1493-1496.
81. Clements PJ. Alkylating Agents. In: Dixon J, Furst DE, eds. Second Line Agents in the Treatment of Rheumatic Diseases. New York: Marcel Dekker; 1991.
82. Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology. 2004;111: 960-965.
83. Lacki JK, Schochat T, Sobieska M, et al. Immunological studies in patients with rheumatoid arthritis treated with methotrexate or cyclophosphamide. Z Rheumatol. 1994;53:76-82.
84. Ahmed AR, Hombal SM. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. J Am Acad Dermatol. 1984;11:1115-1126.
85. Blumenfeld Z, Shapiro D, Shteinberg M, et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus. 2000;9:401-405.
86. Klippel JH, Austin HA III, Balow JE, et al. Studies of immunosuppressive drugs in the treatment of lupus nephritis. Rheum Dis Clin North Am. 1987;13:47-56.
87. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 1997;40:2187-2198.
88. Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 1986;84:527-663.
89. Ando K, Fujino Y, Hijikata K, et al. Epidemiological features and visual prognosis of Behcet's disease. Jpn J Ophthalmol. 1999;43:312-317.
90. Chabner BA, Allegra CA, Curt GA, et al. Antineoplastic Agents. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the Pharmacologic Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1995:1233-1240.
91. Cannon GW, Jackson CG, Samuelson CO Jr, et al. Chlorambucil therapy in rheumatoid arthritis: clinical experience in 28 patients and literature review. Semin Arthritis Rheum. 1985;15:106-118.
92. Dighiero G. Chronic lymphocytic leukemia treatment. Hematol Cell Ther. 1997;39:S31-S40.
93. Miserocchi E, Baltatzis S, Ekong A, et al. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology. 2002;109:137-142.
94. Goldstein DA, Fontanilla FA, Kaul S, et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology. 2002;109:370-377.
95. Mamo JG. Treatment of Behcet disease with chlorambucil. A follow-up report. Arch Ophthalmol. 1976;94:580-583.
96. Tabbara KF. Chlorambucil in Behcet's disease. A reappraisal. Ophthalmology. 1983;90:906-908.
97. Mudun BA, Ergen A, Ipcioglu SU, et al. Short-term chlorambucil for refractory uveitis in Behcet's disease. Ocul Immunol Inflamm. 2001;9:219-229.
98. Yang CS, Liu JH. Chlorambucil therapy in sympathetic ophthalmia. Am J Ophthalmol. 1995;119:482-488.
99. Tessler HH, Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet's disease. Br J Ophthalmol. 1990;74:353-357.
100. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993-2000.
101. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291:2367-2375.
102. Durongpisitkul K, Gururaj VJ, Park JM, et al. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995;96:1057-1061.
103. LeHoang P, Cassoux N, George F, et al. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm. 2000;8:49-57.
104. Rosenbaum JT, George RK, Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol. 1999;127:545-549.
105. Seider N, Beiran I, Scharf J, et al. Intravenous immunoglobulin therapy for resistant ocular Behcet's disease. Br J Ophthalmol. 2001;85:1287-1288.
106. Orion E, Matz H, Wolf R. Interferons: unapproved uses, dosages, or indications. Clin Dermatol. 2002;20:493-504.
107. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467-471.
108. Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423-431.
109. Kotter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin Arthritis Rheum. 2004;33:311-319.
110. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001;358:295-296.
111. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al. Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet. 2001;358:1644.
112. Triolo G, Vadala M, Accardo-Palumbo A, et al. Anti-tumor necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Ann Rheum Dis. 2002;61: 560-561.
113. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology. 2002;109:2342-2346.
114. Rosenbaum JT, Smith JR. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol. 2002;20:S143-S145.
115. Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003;110:1449-1453.
116. Mansour AM. Infliximab treatment of posterior uveitis. Ophthalmology. 2004; 111:197-198.
117. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med. 2004;140:404-406.
118. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352-356.
119. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-1368.
120. Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648-650.
121. Giansanti F, Barbera ML, Virgili G, et al. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease. Eur J Ophthalmol. 2004;14:445-448.
122. Wechsler B, Sable-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behcet's disease. Clin Exp Rheumatol. 2004;22:S14-S16.
123. Rosenbaum JT. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behcet's disease. J Rheumatol. 2004;31:1241-1243.
124. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45:252-257.
125. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18-23.
126. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121:437-440.
127. Nussenblatt RB, Thompson DJ, Li Z, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun. 2003;21:283-293 (Erratum in: J Autoimmun. 2004;23:93).
128. Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology. 2003;110:786-789.
129. McIntosh T, Freeman TR. Anakinra shows promise for treating patients with rheumatoid arthritis. J Am Pharm Assoc (Washington). 2002;42:660-662.
130. Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003;48:927-934.